QPPV.COM KNOWLEDGE ASSESSMENT

Erenumab: CGRP-Receptor Biology, Migraine Prevention and Product Pharmacovigilance

Test your understanding of the concepts covered by Erenumab: CGRP-Receptor Biology, Migraine Prevention and Product Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement best captures the distinction between erenumab's therapeutic action and its potential safety implications?

The same pathway intervention that reduces migraine signalling may also alter gastrointestinal motility and vascular tone Therapeutic effects and safety effects must arise from unrelated biological systems Blocking the CGRP receptor affects only trigeminal pain and cannot influence peripheral physiology Safety concerns arise solely from the injection device and not from pharmacology

Question 2 of 10 Which molecular description of the canonical CGRP receptor is supported by the article?

It is a heteromeric complex including calcitonin receptor-like receptor and receptor activity-modifying protein 1 It is a nuclear receptor formed solely by the serotonin transporter It is an ion channel composed exclusively of CGRP molecules It is a vascular enzyme that directly degrades CGRP

Question 3 of 10 Why is it pharmacologically important that erenumab acts at the CGRP receptor rather than removing circulating CGRP?

Receptor blockade prevents activation at the target even when CGRP remains present Receptor blockade ensures that CGRP cannot be produced by sensory neurons Receptor blockade confines all CGRP activity to the central nervous system Receptor blockade converts erenumab into an acute migraine treatment

Question 4 of 10 Why should a device complaint and an adverse event remain linked when both occur in one report?

The device issue may explain the clinical outcome while still requiring separate assessment as an operational or product problem All device complaints are automatically adverse drug reactions Linkage eliminates the need to document the patient's symptoms Device issues are irrelevant once a patient reports migraine worsening

Question 5 of 10 Which pregnancy-case information is most important for interpreting exposure to erenumab?

Timing of exposure during pregnancy, estimated due date, other migraine therapies and pregnancy outcome Only the patient's preferred injection site Only the number of migraine days before pregnancy Whether the patient used an autoinjector or syringe, without exposure timing

Question 6 of 10 Which information would most improve assessment of a report of new hypertension after erenumab?

Only the patient's migraine aura status Baseline and repeated blood-pressure measurements, timing relative to dosing, comorbidities and antihypertensive treatment The colour and packaging of the autoinjector, without clinical measurements Whether the patient had photophobia during the last migraine

Question 7 of 10 A patient develops angioedema nine days after an erenumab injection. How should timing be interpreted?

The delay rules out erenumab because hypersensitivity must occur immediately The event should be considered potentially relevant because delayed hypersensitivity has been reported The event can only be classified as a device complaint The event should automatically be attributed to migraine biology

Question 8 of 10 Which statement best expresses the appropriate role of mechanism in an individual case causality assessment?

Mechanistic plausibility establishes causality whenever the event is biologically possible Mechanism should guide follow-up and hypothesis formation but should be integrated with chronology, baseline risk, alternatives and dechallenge Mechanism is irrelevant if the event was reported after marketing authorisation Mechanism should replace objective clinical measurements when a known warning exists

Question 9 of 10 Which patient factor would be most relevant as a cofactor when evaluating new or worsening Raynaud's phenomenon?

Use of a vasoconstrictive medicine A history of photophobia during migraine Use of a neutral injection site on the abdomen A previous response to an acute antiemetic

Question 10 of 10 A report states only that the patient's migraine treatment 'did not work' after one injection. What is the most important initial follow-up?

Assume pharmacological failure because any headache proves lack of efficacy Establish baseline migraine frequency, exposure duration and whether the full dose was delivered Classify the report as a serious adverse reaction because efficacy was absent Disregard the report because preventive medicines cannot be assessed in pharmacovigilance

QPPV.com

Erenumab: CGRP-Receptor Biology, Migraine Prevention and Product Pharmacovigilance

Cookie Settings